Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.
about
Phosphoribosyl Diphosphate (PRPP): Biosynthesis, Enzymology, Utilization, and Metabolic Significance.The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia.Additive reductions in zebrafish PRPS1 activity result in a spectrum of deficiencies modeling several human PRPS1-associated diseases.Oligomeric interface modulation causes misregulation of purine 5´-nucleotidase in relapsed leukemia.A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formationTSG-6 secreted by human umbilical cord-MSCs attenuates severe burn-induced excessive inflammation via inhibiting activations of P38 and JNK signalingDeep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.Therapies on the horizon for childhood acute lymphoblastic leukemia.Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.Phosphoribosylpyrophosphate Synthetase 1 Knockdown Suppresses Tumor Formation of Glioma CD133+ Cells Through Upregulating Cell Apoptosis.Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia.Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKIγ.Recent advances in the management of pediatric acute lymphoblastic leukemia.Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group.Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.Conversion of PRPS Hexamer to Monomer by AMPK-Mediated Phosphorylation Inhibits Nucleotide Synthesis in Response to Energy Stress.Mutant PRPS1: a new therapeutic target in relapsed acute lymphoblastic leukemia.HPRT1 activity loss is associated with resistance to thiopurine in ALL.Clonal evolution in leukemia.MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.PRPS1 silencing reverses cisplatin resistance in human breast cancer cells.Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and anti-leukemic efficacy.New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.High expression of PRPS1 induces an anti-apoptotic effect in B-ALL cell lines and predicts an adverse prognosis in Chinese children with B-ALL.Childhood relapsed acute lymphoblastic leukemia: Biology and recent treatment progress.Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic LeukemiaGenetics and epigenetics of pediatric leukemia in the era of precision medicineRevisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
P2860
Q30396867-4E737DAA-7830-42D1-972C-72EB701A3812Q33828913-A4B09212-50F9-473C-9A49-AE520B6FE13DQ34534367-F9AE596E-185D-422E-B241-FC94786A762BQ36166888-2DC2802D-2AC8-4A9C-81E5-9BA8EAB25CD6Q36955860-271399A3-28E6-47FF-98C1-0E0A41370667Q37117528-D787664E-C8B0-4C35-9931-C5043C9CEBD8Q37665574-22469FA3-541D-4F7B-A645-210088BE5621Q38504437-10F6425F-45E4-4823-807A-FC05403CACF5Q38633437-086085FA-C3EF-42A8-8B63-B4A29957B790Q38762311-2E9D2FDA-F34D-4B31-81DA-9FB4D43BCA1FQ38843371-B8F3F133-8C10-48B9-996C-9460DE59CF27Q39041475-7CB85F3C-4AF3-4FAE-A146-36E5FECCC597Q39570917-13EE1623-9F28-4021-97F0-66B0E45BF0D7Q45060698-EBFCA705-0CC8-4FDC-9337-6137ACF21F48Q45105040-5FE3EE58-BA1D-434E-80BA-6A2D36B3F6A4Q46355299-5767B3D7-437F-4174-8B21-EAB5C1D9C198Q47370037-4F56E40F-1764-4E26-A172-B6C67F4CAAD7Q47999164-40316D04-041F-4600-89FB-4085A4DFFCA1Q48178689-56AF1842-D2DB-4DE8-96F0-08ED1019125EQ49324130-DC17CA54-FDBB-461C-8210-3AB835CB665CQ49557852-9DFE2ABC-70B5-4A14-8165-1D2D97873E50Q49959979-E01A714D-ABBB-4C5E-8F0D-ABAA8E1E36A0Q50001759-D8DD7855-685A-47FF-BA2E-62EDA80A40ABQ50145888-5DAD5C85-A6E0-47E1-A792-C528687AFA9CQ50904608-C86AC09B-8DD7-4D7B-9956-C617FA292C26Q51735726-8A1252F3-57A8-4EB3-BEEF-0A0E9B4317BDQ51839566-1BACB2AC-1307-4175-8716-D01F2589FFF4Q52726496-48C76A9C-DC34-4B5F-82D3-F282411A613AQ53814000-FFC68102-F3F0-4210-9D07-51B87B502449Q56967108-FD8F6DCC-738D-4016-8F6E-B24FD970241CQ57175475-1C8E4D58-C4FC-41FD-91A8-599BE8577414Q57817595-A34ADD7B-BAFF-49B0-87D2-14BD8EC6429D
P2860
Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Negative feedback-defective PR ...... nce in relapsed childhood ALL.
@ast
Negative feedback-defective PR ...... nce in relapsed childhood ALL.
@en
type
label
Negative feedback-defective PR ...... nce in relapsed childhood ALL.
@ast
Negative feedback-defective PR ...... nce in relapsed childhood ALL.
@en
prefLabel
Negative feedback-defective PR ...... nce in relapsed childhood ALL.
@ast
Negative feedback-defective PR ...... nce in relapsed childhood ALL.
@en
P2093
P2860
P356
P1433
P1476
Negative feedback-defective PR ...... nce in relapsed childhood ALL.
@en
P2093
Adolfo Ferrando
Benshang Li
Bin-Bing S Zhou
Gannie Tzoneva
Haisong Lu
Hongzhuan Chen
Huanhuan Liang
P2860
P2888
P304
P356
10.1038/NM.3840
P407
P577
2015-05-11T00:00:00Z
P5875
P6179
1033127948